Description

A focused course, tailored for you

FDA Submission Mastery for Regulatory Affairs

Build packages that clear FDA review without triggering an information request.

Information requests reset the FDA review clock and signal to reviewers that your package had preventable gaps. For regulatory affairs professionals in biomedical research, the cost is not just time: it is credibility with the sponsor, the review division, and the clinical team waiting on approval.

$199 one-time

Tailored to your situation. Access within 24 hours. 30-day money-back.

Includes a hand-built implementation playbook delivered alongside course access, generated for your specific situation.

Why this course

Every submission package you build carries risk that the reviewer will stop on a question you could have answered before filing. The gap might be a missing cross-reference in the technical narrative, an evidence section that does not map cleanly to the review criteria, or a labelling claim the reviewer cannot verify from the data provided. None of these are knowledge gaps. They are organisation and structure gaps. The FDA review process rewards submissions where the reviewer can move through the package without pausing to ask. Building that quality requires a disciplined pre-submission gap analysis, a technical narrative framework that mirrors how the reviewer reads, and an evidence packaging method that survives the transition from internal authoring to external review. Without that method, the IR rate is higher than it needs to be and the review clock extends in ways that compound across a portfolio of submissions.

What you walk away with

Apply a pre-submission gap analysis checklist that maps each section of your package to the FDA review criteria before filing.
Write a technical narrative structure that mirrors the reviewer's reading sequence, reducing the likelihood of mid-review information requests.
Organise evidence packages for IND, 510(k), and PMA submissions using a section-by-section mapping method.
Build a labelling and claims verification checklist that confirms each claim is traceable to study data included in the submission.
Execute an information request response protocol that closes the IR quickly and strengthens the original submission record.
Manage cross-functional submission teams using a responsibility matrix that prevents last-minute evidence gaps.

The 12 modules

Module 1. How FDA Reviewers Read a Submission

Before building any submission package, you need to understand the reviewer's sequence. This module maps the FDA review workflow for drug, device, and combination product submissions, showing which sections the reviewer opens first, where gaps most commonly trigger questions, and how the administrative completeness check differs from the substantive review. You will leave with a reviewer-perspective checklist you can apply to any package before it leaves your desk.

Module 2. The Pre-Submission Gap Analysis

The IR prevention habit starts before you finalise the table of contents. This module teaches a structured gap analysis method: mapping each submission section to the specific review criterion it must satisfy, identifying missing cross-references, flagging evidence sections where the data does not directly support the claim, and surfacing labelling inconsistencies before the reviewer sees them. The downloadable gap analysis worksheet works for IND, 510(k), and PMA formats.

Module 3. Technical Narrative Structure for Drug Submissions

For IND and NDA submissions, the technical narrative is the document FDA reviewers read most closely. This module covers the section-by-section narrative template that anticipates reviewer questions: safety rationale in the order the reviewer will interrogate it, pharmacology and toxicology summaries with explicit cross-references to the data sections, and the clinical protocol summary structure that aligns with 21 CFR Part 312 expectations. Each section includes annotated examples of reviewer-friendly and reviewer-unfriendly formatting.

Module 4. 510(k) Substantial Equivalence Evidence Packaging

The 510(k) review turns on whether your device is substantially equivalent to a predicate. This module covers the evidence packaging method for the predicate comparison: technology comparison tables that map feature-by-feature, performance testing data organised by the applicable FDA guidance document, and the labelling comparison section that closes the equivalence argument without overreaching. You will also work through the common gaps that produce Additional Information (AI) requests in the 510(k) pathway.

Module 5. PMA Submission Architecture

Pre-Market Approval submissions are the most document-intensive pathway. This module covers the modular PMA structure: how to organise the administrative, technical, and clinical sections so the review team can locate every supporting document without requesting an index correction. Key areas covered include the clinical data summary that aligns with FDA's statistical review expectations, the manufacturing section that satisfies CAPA and QSR requirements, and the benefit-risk framework FDA reviewers apply to novel device technologies.

Module 6. Labelling and Claims Verification

Labelling claims that cannot be traced to study data in the submission are a consistent source of information requests. This module teaches the claims-to-evidence traceability method: mapping each indication, warning, and precaution to the specific data table that supports it, reviewing labelling against the approved predicate where applicable, and the internal review protocol that catches unsupported claims before filing. The downloadable claims matrix covers drug, device, and combination product formats.

Module 7. Managing Cross-Functional Submission Teams

Submission gaps often originate in hand-offs between clinical, manufacturing, medical writing, and regulatory teams. This module covers the submission responsibility matrix: assigning section ownership, setting internal deadlines that provide gap-analysis time before the filing date, managing late evidence from manufacturing or clinical operations, and the sign-off protocol that confirms each section owner has reviewed the cross-references their section depends on. The downloadable RACI template is sized for a four-to-eight person submission team.

Module 8. Writing Responses to FDA Information Requests

When an IR arrives, the response quality determines whether the review clock extends once or several times. This module covers the IR response structure: identifying whether the FDA question requires new data, a clarification, or a cross-reference fix; drafting a response that closes the question without introducing new gaps; and the internal review step that prevents the response from triggering a second IR. Worked examples cover IND safety reporting, 510(k) performance data, and PMA clinical data queries.

Module 9. Complete Response Letter Management

A Complete Response Letter signals that the submission cannot be approved as filed and requires resubmission or a meeting with the review division. This module covers the CRL analysis workflow: categorising the deficiencies, prioritising the response strategy, deciding whether to request a Type A meeting or proceed directly to resubmission, and building the resubmission package that closes each deficiency with traceable evidence. Includes a downloadable CRL deficiency classification worksheet.

Module 10. Pre-Submission Meetings and Q-Submissions

The most effective IR prevention tool is the pre-submission meeting. This module covers the Q-Submission program: when to request a Pre-Sub meeting versus proceeding directly to filing, how to frame the questions that generate binding FDA guidance, preparing the briefing document that maximises the value of the meeting, and incorporating FDA feedback into your submission architecture before you file. The module covers Pre-Sub strategy for both device and drug pathways, including combination products.

Module 11. Combination Product Submission Specifics

Combination products spanning drug-device or biologic-device categories require coordinated submission strategies across FDA centres. This module covers the Request for Designation (RFD) process for establishing the lead centre, the co-review coordination requirements, the CMC and device technical sections that must satisfy both CDER/CBER and CDRH standards, and the labelling conventions that apply to combination products with components regulated under different product codes. The downloadable checklist covers the most common drug-device combination product formats.

Module 12. Building Your Submission Quality System

Sustained low-IR performance across a portfolio requires a quality system, not a single submission improvement. This module covers the metrics worth tracking (IR rate by submission type, days-to-response, first-cycle approval rate), the post-submission review process that updates the gap analysis checklist, and the knowledge base structure that makes your team's expertise cumulative rather than locked in individual contributors. Closes with a 90-day plan for embedding these practices in your regulatory function.

How this addresses your situation

Specific modules that map to what you said you are dealing with.

You are preparing an IND and want to reduce the likelihood of FDA safety questions during the review period.

You are managing a 510(k) submission where the predicate comparison section is complex and the performance data is spread across multiple testing labs.

You received an information request and need to write a response that closes the FDA question without opening new gaps.

You are building a quality system for your regulatory function and want to track and reduce your team's IR rate over time.

What you get with this course

Twelve written modules covering the full FDA submission quality lifecycle from gap analysis to CRL management.
Downloadable templates: pre-submission gap analysis worksheet, 510(k) evidence packaging map, claims-to-evidence traceability matrix, cross-functional RACI for submission teams, CRL deficiency classification worksheet, 90-day implementation plan.
Worked examples of reviewer-friendly and reviewer-unfriendly technical narrative sections.
Hand-built implementation playbook delivered alongside course access, tailored to your submission type and regulatory portfolio.

What you will have in hand by Day 1, Week 1, Month 1

Course access and the hand-built implementation playbook are both delivered within 24 hours of purchase.

Before and after

Before

Submissions go through the FDA review cycle with information requests that reset the clock. The IR response process is reactive and each request requires fresh coordination across clinical, manufacturing, and medical writing teams.

After

Each submission package passes a pre-submission gap analysis before filing. Technical narratives are structured to anticipate FDA questions. IR frequency drops and the response process follows a repeatable protocol that resolves requests in the first response.

What happens if you do not address this

Each information request that could have been prevented costs weeks of review time, requires cross-functional coordination to resolve, and compounds across a submission portfolio. At the portfolio level, a persistently elevated IR rate is visible to sponsors and to the FDA review division, and it shapes the review relationship for future submissions.

Who it is for

Regulatory affairs professionals in biomedical research responsible for FDA submission packages: IND applications, 510(k) premarket notifications, PMA submissions, or combination product dossiers. You coordinate between clinical, manufacturing, and medical writing teams to produce submissions that must satisfy FDA reviewers. You have filed submissions before and know the IR process from the inside. This course is for building the gap-prevention and narrative-structuring skills that reduce IR frequency across your submission portfolio.

Who this is NOT for. Professionals in post-market surveillance only, or those whose submissions are handled entirely by external CROs with no internal regulatory team involvement. This course assumes direct authoring or review responsibility for FDA submission packages.

How it arrives

Text-based course in the Art of Service learning environment, plus downloadable templates and worked examples for every module, plus the hand-built implementation playbook delivered alongside course access.

Time investment. Each module is designed to be completed in 30 to 45 minutes. The full course takes approximately six to eight hours spread across your schedule. The downloadable templates can be applied to live submissions from the first module onward.

Why $199 is the right number

FDA regulatory training programmes from professional associations cover the regulatory framework in depth but rarely focus on the submission construction and IR-prevention skills that determine first-cycle approval rates. CRO-provided submission support delivers a package but does not build the internal capability to maintain submission quality across a portfolio. This course teaches the gap analysis, narrative structuring, and evidence packaging skills that reduce IR frequency for your own team's submissions.

FAQ

Does this course cover both drug and device submissions?

Yes. The course covers IND and NDA submissions (drug pathway), 510(k) and PMA submissions (device pathway), and combination products. Where the requirements differ between pathways, the module notes the distinction explicitly.

I already have submission experience. Will this be too basic?

The course assumes you have filed submissions before and know the FDA review process from the inside. It focuses on the gap-prevention and narrative-structuring skills that experienced professionals use to reduce IR frequency, not on explaining what an IND or 510(k) is.

How is the implementation playbook tailored to my situation?

After purchase, you receive a brief intake question about your current submission type and regulatory portfolio. The hand-built playbook is built from your answer and delivered within 24 hours alongside course access. Reply to this email with any questions.

30-day money-back guarantee. If after a week of working through the materials this is not what you needed, reply to the receipt email and a full refund is processed. No questions, no forms.

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.